nach oben

Erschienen in:

27.10.2015 | Original Article

Novel MicroRNA signatures in HPV-mediated cervical carcinogenesis in Indian women

verfasst von: Shweta Sharma, Showket Hussain, Kartik Soni, Pallavi Singhal, Richa Tripathi, V. G. Ramachandran, Sonal Sharma, Shukla Das, Beena Pillai, Mausumi Bharadwaj

Erschienen in: Tumor Biology | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

This study aimed to investigate the role of miRNAs in HPV-mediated cervical pre-cancer and cancer cases in Indian population. We analysed the HPV infection and its genotypes in uterine cervical pre-cancer (n = 80), cancer (n = 200) and normal cervical samples (n = 150) by consensus sequence PCR followed by type specific PCRs. Also, microRNA profiling was done in a subset of cervical pre-cancer (n = 20), cancer cases (n = 50) and normal samples (n = 30) by real-time quantitative PCR (qRT-PCR). The prevalence of HPV infection in pre-cancer was found to be 81 % (65/80) and 94 % (188/200) in cancer cases, with most predominant high-risk HPV type-16 (HR-HPV-16) in 83 % of cancer and 91 % of pre- cancer cases, respectively. Whereas in controls, the HPV infection was found to be very low (5 %). The miRNA profiling revealed that in cervical pre-cancer, 100 miRNAs were significantly (p < 0.001) differentially expressed with 70 miRNAs upregulated and 30 miRNAs downregulated. In cervical cancer cases, 383 miRNA were found to be differentially expressed (p < 0.001), of which 350 miRNAs were upregulated and 33 miRNAs were downregulated. We also observed that 182 miRNAs were differentially expressed (p < 0.001) in HPV-16/18-positive (SiHa/HeLa) cell lines compared with HPV-negative (C33A) cell line. In addition, we identified the novel microRNAs such as miR-892b, miR-500, miR-888, miR-505 and miR-711 in cervical precancerous lesions and cervical cancer cases in Indian population. Taken together, the study demonstrates a crucial role of microRNAs in cervical cancer, which may serve as potential early diagnostic markers for cervical carcinogenesis.

Ambros V, Bartel B, Bartel DP, Burge CB, Carrington JC, Chen X, et al. A uniform system for microRNA annotation. RNA. 2003;9:277–9.CrossRefPubMedPubMedCentral

Esquela-Kerscher A, Slack FJ. Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259–69.CrossRefPubMed

Lytle JR, Yario TA, Steitz JA. Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5′ UTR as in the 3′ UTR. Proc Natl Acad Sci U S A. 2007;104:9667–72.CrossRefPubMedPubMedCentral

Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A. 2004;101:2999–3004.CrossRefPubMedPubMedCentral

Suzuki HI, Yamagata K, Sugimoto K, Iwamoto T, Kato S, Miyazono K. Modulation of microRNA processing by p53. Nature. 2009;460:529–33.CrossRefPubMed

Reshmi G, Pillai MR. Beyond HPV: oncomirs as new players in cervical cancer. FEBS Lett. 2008;582:4113–6.CrossRefPubMed

Das BC, Hussain S, Nasare V, Bharadwaj M. Prospects and prejudices of human papillomavirus vaccines in India. Vaccine. 2008;26:2669–79.CrossRefPubMed

zur Hausen H. Human papillomaviruses and their possible role in squamous cell carcinomas. Curr Top Microbiol Immunol. 1977;78:1–30.PubMed

Hussain S, Nasare V, Kumari M, Sharma S, Khan MA, Das BC, et al. Perception of human papillomavirus infection, cervical cancer and HPV vaccination in North Indian population. PLoS One. 2014;9:e112861.

10.

zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2:342–50.CrossRefPubMed

11.

Kavitha N, Vijayarathna S, Jothy SL, Oon CE, Chen Y, Kanwar JR, et al. MicroRNAs: biogenesis, roles for carcinogenesis and as potential biomarkers for cancer diagnosis and prognosis. Asian Pac J Cancer Prev. 2014;15:7489–97.CrossRefPubMed

12.

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.CrossRefPubMed

13.

Das BC, Sharma JK, Gopalakrishna V, Luthra UK. Analysis by polymerase chain reaction of the physical state of human papillomavirus type 16 DNA in cervical preneoplastic and neoplastic lesions. J Gen Virol. 1992;73(Pt 9):2327–36.CrossRefPubMed

14.

Hussain S, Bharti AC, Salam I, Bhat MA, Mir MM, Hedau S, et al. Transcription factor AP-1 in esophageal squamous cell carcinoma: alterations in activity and expression during human Papillomavirus infection. BMC Cancer. 2009;9:329.CrossRefPubMedPubMedCentral

15.

Ouyang M, Li Y, Ye S, Ma J, Lu L, Lv W, et al. MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer. PLoS One. 2014;9:e96228.

16.

Mazan-Mamczarz K, Gartenhaus RB. Role of microRNA deregulation in the pathogenesis of diffuse large B-cell lymphoma (DLBCL). Leuk Res. 2013;37:1420–8.CrossRefPubMed

17.

Dong Y, Wu WK, Wu CW, Sung JJ, Yu J, Ng SS. MicroRNA dysregulation in colorectal cancer: a clinical perspective. Br J Cancer. 2011;104:893–8.CrossRefPubMedPubMedCentral

18.

Tumilson CA, Lea RW, Alder JE, Shaw L. Circulating microRNA biomarkers for glioma and predicting response to therapy. Mol Neurobiol. 2014;50:545–58.CrossRefPubMed

19.

Maugeri-Sacca M, Coppola V, Bonci D, De Maria R. MicroRNAs and prostate cancer: from preclinical research to translational oncology. Cancer J. 2012;18:253–61.CrossRef

20.

Shishodia G, Shukla S, Srivastava Y, Masaldan S, Mehta S, Bhambhani S, et al. Alterations in microRNAs miR-21 and let-7a correlate with aberrant STAT3 signaling and downstream effects during cervical carcinogenesis. Mol Cancer. 2015;14:116.CrossRefPubMedPubMedCentral

21.

Gocze K, Gombos K, Kovacs K, Juhasz K, Gocze P, Kiss I. MicroRNA expressions in HPV-induced cervical dysplasia and cancer. Anticancer Res. 2015;35:523–30.PubMed

22.

Li B, Hu Y, Ye F, Li Y, Lv W, Xie X. Reduced miR-34a expression in normal cervical tissues and cervical lesions with high-risk human papillomavirus infection. Int J Gynecol Cancer. 2010;20:597–604.CrossRefPubMed

23.

Greco D, Kivi N, Qian K, Leivonen SK, Auvinen P, Auvinen E. Human papillomavirus 16 E5 modulates the expression of host microRNAs. PLoS One. 2011;6:e21646

24.

Yang X, Ni W, Lei K. miR-200b suppresses cell growth, migration and invasion by targeting Notch1 in nasopharyngeal carcinoma. Cell Physiol Biochem. 2013;32:1288–98.CrossRefPubMed

25.

Wong CM, Wei L, Au SL, Fan DN, Zhou Y, Tsang FH, et al. MiR-200b/200c/429 subfamily negatively regulates Rho/ROCK signaling pathway to suppress hepatocellular carcinoma metastasis. Oncotarget. 2015;6:13658–70.CrossRefPubMedPubMedCentral

26.

Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, et al. MicroRNA signatures in human ovarian cancer. Cancer Res. 2007;67:8699–707.CrossRefPubMed

27.

Pignot G, Cizeron-Clairac G, Vacher S, Susini A, Tozlu S, Vieillefond A, et al. microRNA expression profile in a large series of bladder tumors: identification of a 3-miRNA signature associated with aggressiveness of muscle-invasive bladder cancer. Int J Cancer. 2013;132:2479–91.CrossRefPubMed

28.

Yoneyama K, Ishibashi O, Kawase R, Kurose K, Takeshita T. miR-200a, miR-200b and miR-429 are onco-miRs that target the PTEN gene in endometrioid endometrial carcinoma. Anticancer Res. 2015;35:1401–10.PubMed

29.

Feng B, Wang R, Chen LB. Review of miR-200b and cancer chemosensitivity. Biomed Pharmacother. 2012;66:397–402.CrossRefPubMed

30.

Li X, Xin S, He Z, Che X, Wang J, Xiao X, et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor PDCD4 and promotes cell transformation, proliferation, and metastasis in renal cell carcinoma. Cell Physiol Biochem. 2014;33:1631–42.CrossRefPubMed

31.

Zhang JG, Wang JJ, Zhao F, Liu Q, Jiang K, Yang GH. MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). Clin Chim Acta. 2010;411:846–52.CrossRefPubMed

32.

Lin SL, Chiang A, Chang D, Ying SY. Loss of mir-146a function in hormone-refractory prostate cancer. RNA. 2008;14:417–24.CrossRefPubMedPubMedCentral

33.

Rong M, He R, Dang Y, Chen G. Expression and clinicopathological significance of miR-146a in hepatocellular carcinoma tissues. Ups J Med Sci. 2014;119:19–24.CrossRefPubMedPubMedCentral

34.

Singh N, Hussain S, Kakkar N, Singh SK, Sobti RC, Bharadwaj M. Implication of high risk human papillomavirus HR-HPV infection in prostate cancer in Indian population—-a pioneering case–control analysis. Sci Rep. 2015;5:7822.

35.

Xie H, Zhao Y, Caramuta S, Larsson C, Lui WO. miR-205 expression promotes cell proliferation and migration of human cervical cancer cells. PLoS One. 2012;7:e46990.

36.

Zhao J, Xu G, Qian YW, Li YW. Down-regulation of miR-205 promotes stemness of hepatocellular carcinoma cells by targeting PLCbeta1 and increasing CD24 expression. Neoplasma. 2015;62(4);567–73.

37.

Severino P, Oliveira LS, Andreghetto FM, Torres N, Curioni O, Cury PM, et al. Small RNAs in metastatic and non-metastatic oral squamous cell carcinoma. BMC Med Genomics. 2015;8:31.CrossRefPubMedPubMedCentral

38.

Bai J, Zhu X, Ma J, Wang W. miR-205 regulates A549 cells proliferation by targeting PTEN. Int J Clin Exp Pathol. 2015;8:1175–83.PubMedPubMedCentral

39.

Geng D, Song X, Ning F, Song Q, Yin H. MiR-34a inhibits viability and invasion of human papillomavirus-positive cervical cancer cells by targeting E2F3 and regulating survivin. Int J Gynecol Cancer. 2015;25:707–13.CrossRefPubMed

40.

Honegger A, Schilling D, Bastian S, Sponagel J, Kuryshev V, Sultmann H, et al. Dependence of intracellular and exosomal microRNAs on viral E6/E7 oncogene expression in HPV-positive tumor cells. PLoS Pathog. 2015;11:e1004712

41.

He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, et al. A microRNA component of the p53 tumour suppressor network. Nature. 2007;447:1130–4.CrossRefPubMedPubMedCentral

42.

Coutinho-Camillo CM, Lourenco SV, Lima LA, Kowalski LP, Soares FA. Expression of apoptosis-regulating miRNAs and target mRNAs in oral squamous cell carcinoma. Canc Genet. 2015;208(7–8):382–9.CrossRef

43.

Zhao Z, Wang L, Song W, Cui H, Chen G, Qiao F, et al. Reduced miR-29a-3p expression is linked to the cell proliferation and cell migration in gastric cancer. World J Surg Oncol. 2015;13:101.CrossRefPubMedPubMedCentral

44.

Li Y, Wang F, Xu J, Ye F, Shen Y, Zhou J, et al. Progressive miRNA expression profiles in cervical carcinogenesis and identification of HPV-related target genes for miR-29. J Pathol. 2011;224:484–95.CrossRefPubMed

45.

Martinez I, Gardiner AS, Board KF, Monzon FA, Edwards RP, Khan SA. Human papillomavirus type 16 reduces the expression of microRNA-218 in cervical carcinoma cells. Oncogene. 2008;27:2575–82.CrossRefPubMed

46.

Yamamoto N, Kinoshita T, Nohata N, Itesako T, Yoshino H, Enokida H, et al. Tumor suppressive microRNA-218 inhibits cancer cell migration and invasion by targeting focal adhesion pathways in cervical squamous cell carcinoma. Int J Oncol. 2013;42:1523–32.PubMedPubMedCentral

47.

Liu X, Lang J, Wu S, Cheng L, Wang W, Zhu L. Differential expression of microRNAs in periurethral vaginal wall tissues of postmenopausal women with and without stress urinary incontinence. Menopause. 2014;21:1122–8.CrossRefPubMed

48.

Venkatesan N, Deepa PR, Khetan V, Krishnakumar S. Computational and in vitro Investigation of miRNA-gene regulations in retinoblastoma pathogenesis: miRNA mimics strategy. Bioinform Biol Insights. 2015;9:89–101.PubMedPubMedCentral

49.

Yamamoto Y, Kosaka N, Tanaka M, Koizumi F, Kanai Y, Mizutani T, et al. MicroRNA-500 as a potential diagnostic marker for hepatocellular carcinoma. Biomarkers. 2009;14:529–38.CrossRefPubMed

50.

Zhang L, Ding Y, Yuan Z, Liu J, Sun J, Lei F, et al. MicroRNA-500 sustains nuclear factor-kappaB activation and induces gastric cancer cell proliferation and resistance to apoptosis. Oncotarget. 2015;6:2483–95.CrossRefPubMedPubMedCentral

51.

Hovey AM, Devor EJ, Breheny PJ, Mott SL, Dai D, Thiel KW, et al. miR-888: a novel cancer-testis antigen that targets the progesterone receptor in endometrial cancer. Trans Oncol. 2015;8:85–96.CrossRef

52.

Huang S, Chen L. MiR-888 regulates side population properties and cancer metastasis in breast cancer cells. Biochem Biophys Res Commun. 2014;450:1234–40.CrossRefPubMed

53.

Molina-Pinelo S, Carnero A, Rivera F, Estevez-Garcia P, Bozada JM, Limon ML, et al. MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer. BMC Cancer. 2014;14:656.CrossRefPubMedPubMedCentral

54.

Matamala N, Vargas MT, Gonzalez-Campora R, Minambres R, Arias JI, Menendez P, et al. Tumor MicroRNA expression profiling identifies circulating MicroRNAs for early breast cancer detection. Clin Chem. 2015;61(8):1098–106.

55.

Ninomiya M, Kondo Y, Funayama R, Nagashima T, Kogure T, Kakazu E et al. Distinct microRNAs expression profile in primary biliary cirrhosis and evaluation of miR 505-3p and miR197-3p as novel biomarkers. PLoS One. 2013;8:e66086.

56.

Ralfkiaer U, Lindahl LM, Litman T, Gjerdrum LM, Ahler CB, Gniadecki R, et al. MicroRNA expression in early mycosis fungoides is distinctly different from atopic dermatitis and advanced cutaneous T-cell lymphoma. Anticancer Res. 2014;34:7207–17.PubMed

57.

Ma Q, Wan G, Wang S, Yang W, Zhang J, Yao X. Serum microRNA-205 as a novel biomarker for cervical cancer patients. Cancer Cell Int. 2014;14:81.CrossRefPubMedPubMedCentral

58.

Singh N, Sobti RC, Suri V, Nijhawan R, Sharma S, Das BC, et al. Downregulation of tumor suppressor gene PML in uterine cervical carcinogenesis: impact of human papillomavirus infection (HPV). Gynecol Oncol. 2013;128:420–6.CrossRefPubMed

59.

Singhal P, Hussain S, Thakur N, Batra S, Salhan S, Bhambani S, et al. Association of MDM2 and p53 polymorphisms with the advancement of cervical carcinoma. DNA Cell Biol. 2013;32:19–27.CrossRefPubMed

60.

Hussain S, Bharadwaj M, Nasare V, Kumari M, Sharma S, Hedau S, et al. Human papillomavirus infection among young adolescents in India: impact of vaccination. J Med Virol. 2012;84:298–305.CrossRefPubMed

61.

Krishnan S, Sivaram S, Anderson BO, Basu P, Belinson JL, Bhatla N, et al. Using implementation science to advance cancer prevention in India. Asian Pac J Cancer Prev. 2015;16:3639–44.CrossRefPubMed

Titel: Novel MicroRNA signatures in HPV-mediated cervical carcinogenesis in Indian women
verfasst von: Shweta Sharma
Showket Hussain
Kartik Soni
Pallavi Singhal
Richa Tripathi
V. G. Ramachandran
Sonal Sharma
Shukla Das
Beena Pillai
Mausumi Bharadwaj
Publikationsdatum: 27.10.2015
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 4/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-4248-7

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

Novel MicroRNA signatures in HPV-mediated cervical carcinogenesis in Indian women

Abstract

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2016

The α7-nicotinic acetylcholine receptor mediates the sensitivity of gastric cancer cells to taxanes

miR-198 targets SHMT1 to inhibit cell proliferation and enhance cell apoptosis in lung adenocarcinoma

RRP12 is a crucial nucleolar protein that regulates p53 activity in osteosarcoma cells

The involvement of myocyte enhancer factor 2D in regulating tumor biology of cardiac myxoma

Role of estrogen receptor alpha in human cervical cancer-associated fibroblasts: a transcriptomic study

Overexpression of OCT4 contributes to progression of hepatocellular carcinoma

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie